Pharma Tech

FDA expands J&J’s Rybrevant Faspro label with head and neck cancer approval

Nov 6, 2026, 11:34 AM

Read Full Article → FDA expands J&J’s Rybrevant Faspro label with head and neck cancer approval

Translate article text

Choose a language and wait for the translated text.

The accelerated approval marks the first indication beyond lung cancer for J&J’s bispecific antibody.